




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : C12N 7/01, 15/85, 15/86, 15/79</p>	<p>A1</p>	<p>(11) International Publication Number: WO 94/13788 (43) International Publication Date: 23 June 1994 (23.06.94)</p>
<p>(21) International Application Number: PCT/US93/11728 (22) International Filing Date: 3 December 1993 (03.12.93) (30) Priority Data: 989,841 4 December 1992 (04.12.92) US (71) Applicant: UNIVERSITY OF PITTSBURGH [US/US]; 3200 Cathedral of Learning, Pittsburgh, PA 15260-6404 (US). (72) Inventors: SAMULSKI, Richard, J.; 5262 Beeler Street, Pittsburgh, PA 15217 (US). XIAO, Xiao; 3416 Redhook Lane, Alameda, CA 94502 (US). (74) Agents: CORUZZI, Laura, A. et al.; Pennie & Edmonds, 1155 Avenue of the Americas, New York, NY 10036 (US).</p>	<p>(81) Designated States: FI, JP, KR, NO, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i></p>	

(54) Title: RECOMBINANT VIRAL VECTOR SYSTEM



(57) Abstract

The present invention relates to a system for replication and encapsidation of recombinant DNA fragments, as shown in the figure, into virus particles comprised of adenovirus associated viral (AAV) capsid proteins. The invention provides a means of obtaining recombinant viral stocks that may be used to treat patients suffering from genetic diseases.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Larvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MD	Republic of Moldova	TJ	Tajikistan
DE	Germany	MG	Madagascar	TT	Trinidad and Tobago
DK	Denmark	ML	Mali	UA	Ukraine
ES	Spain	MN	Mongolia	US	United States of America
FI	Finland			UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

RECOMBINANT VIRAL VECTOR SYSTEM1. INTRODUCTION

The present invention relates to a system for replication and encapsidation of recombinant DNA fragments into virus particles comprised of adenovirus associated viral (AAV) capsid proteins. The invention provides a means of obtaining recombinant viral stocks that may be used to treat patients suffering from genetic diseases.

10

2. BACKGROUND OF THE INVENTION

The most well studied models for gene therapy involve gene transfer using recombinant pathogenic viruses to express new genetic information in order to correct disease phenotypes. Until recently, the most widely researched viral vectors for use in gene therapy were the retroviruses (Miller, A.D., 1990, Human Gene Ther. 1:5-14). A number of difficulties are associated with retroviral use, including the random integration of retroviruses into the host genome which may lead to insertional mutagenesis, or the inadvertent activation of protooncogene expression due to the promoter activity associated with retroviral LTRs (long terminal repeats). Recent evidence using retrovirus vectors in non-human primates has resulted in T cell lymphomas. Efforts in the field of gene therapy have more recently concentrated on the development of viral vectors lacking these particular characteristics.

20
25
30

AAV can assume two pathways upon infection into the host cell. In the presence of helper virus, AAV will enter the lytic cycle whereby the viral genome is transcribed, replicated, and encapsidated into newly formed viral particles. In the absence of helper virus function, the AAV genome will integrate

35

as a provirus into a specific region of the host cell genome through recombination between the AAV termini and host cell sequences (Cheung, A. et al., 1980, J. Virol. 33:739-748; Berns, K.I. et al., 1982, in Virus Persistence, eds. Mahey, B.W.J., et al. (Cambridge Univ. Press, Cambridge), pp. 249-265).

Characterization of the proviral integration site and analysis of flanking cellular sequences indicates specific targeting of AAV viral DNA into the long arm of human chromosome 19 (Kotin, R.M. et al., 1990, Proc. Natl. Acad. Sci. USA 87:2211-2215; Samulski, R.J. et al., 1991, EMBO J. 10:3941-3950). This particular feature of AAV reduces the likelihood of insertional mutagenesis resulting from random integration of viral vector DNA into the coding region of a host gene. Furthermore, in contrast to the retroviral LTR sequences, the AAV ITR (inverted terminal repeat) sequences appear to be devoid of transcriptional regulatory elements, reducing the risk of insertional activation of protooncogenes.

The AAV genome is composed of a linear single stranded DNA molecule of 4680 nucleotides which contains major open reading frames coding for the *Rep* (replication) and *Cap* (capsid) proteins. Flanking the AAV coding regions are two 145 nucleotide inverted terminal (ITR) repeat sequences that contain palindromic sequences that can fold over to form hairpin structures that function as primers during initiation of DNA replication (FIG. 1). Furthermore, experimental observations indicated that the ITR sequences were needed for viral integration, rescue from the host genome and encapsidation of viral nucleic acid into mature virions [Muzyczka, N. 1992, Current Topics in Microbiology & Immunology. 158, 97-129].

Recent work with AAV has been facilitated by the discovery that AAV sequences cloned into prokaryotic vectors are infectious [Samulski, et al. 1982, Proc. Natl. Acad. Sci. U.S.A. 79:2077-2081].

5 When a plasmid containing intact AAV genome is transfected into cells in the presence of helper virus, AAV can be rescued out from the plasmid vector and enter the lytic pathway leading to production of mature virions. In the absence of helper virus the
10 recombinant AAV vector will integrate into the host cell genome and remain as a provirus until the cell subsequently becomes infected with a helper virus.

3. SUMMARY OF THE INVENTION

15 The invention relates to the *in vitro* synthesis of a novel 165 basepair fragment of DNA which contains AAV ITR sequences and which can be synthesized *in vitro* and used to engineer expression vectors and/or vectors useful for genetic therapy.
20 This 165 bp DNA sequence, herein referred to as the double-D ITR sequence, is in a novel configuration not found to exist in wild type AAV.

The invention is based, in part, on the ability of the double-D ITR sequence to provide
25 sufficient information, *in cis*, for converting a circular duplex DNA molecule into a linear replicating molecule with covalently closed ends, encapsidation into AAV virions, or integration into the host genome. The invention provides an *in vivo* system for
30 replication and packaging of recombinant DNA fragments into mature virions. The resulting recombinant viral stocks afford a convenient and efficient means for transfer of genetic information into any cell or tissue of choice. The system may have applications in
35 gene therapy where the desired goal is correction of a

given genetic abnormality through expression of the normal complement of the defective gene.

The invention also relates to *in vitro* treatment of recombinant viral vectors and/or vectors
5 useful for genetic therapy with bacterial gamma delta resolvase prior to transfection. Genetic engineering of resolvase recognition sequences into recombinant
10 vectors creates the option of removing bacterial plasmid sequences which would normally be included as part of the linear, replicated, and encapsidated DNA molecule. Removal of these bacterial sequences, prior to replication and encapsidation, allows the maximum amount of space for insertion of foreign DNA sequences of interest into the expression vectors.

15 The invention is described by way of examples in which an AAV double-D ITR fragment is amplified in a polymerase chain reaction (PCR) and inserted into a plasmid vector. A viral stock, containing the recombinant DNA encapsidated into
20 mature virions, may be obtained by transfection of the expression vector into a host cell expressing helper functions.

4. BRIEF DESCRIPTION OF THE DRAWINGS

25 FIG. 1. AAV rescue and replication mechanisms. (A) Inverted terminal repeats (ITR) may fold back through the base-pairing of A,A', B,B',C,C' sequences to form a T-shape structure. (B) Excision of infectious plasmid at the ITR sites yields two
30 linear DNA fragments : AAV and the plasmid vector. (C) Predicted fragments generated from double D plasmid after rescue from plasmid circular form to linear with covalent closed ends.

35 FIG. 2. Rescue Intermediate from circular DD-ITR plasmid.

FIG. 3. Replication assay for the plasmid containing the double-D inverted terminal repeat. Plasmid pDD-2 was transfected into Ad5 infected 293 cells with or without cotransfection of the helper plasmid pAAV/Ad. Low molecular weight DNA was extracted 48 hrs. post infection and separated on a 1% agarose gel with or without DpnI digestion. (A)- Ethidium bromide staining of the gel. (B) Southern blot with ³²P labeled plasmid pGEM 3z probe.

FIG. 4. Comparison of replication of pDD-2 with psub201 and pSM620. Plasmid pDD-2 was cotransfected with equal amounts of either pAAV/Ad (lane 1), psub201 (lane2) or pSM620 (lane3) into Ad5 infected 293 cells. Low molecular weight DNA was extracted and digested with DpnI and analyzed on a 1% agarose gel. (A) Ethidium bromide staining. (B) Southern blot with an ITR oligonucleotide probe.

FIG. 5. Replication assay for double-D plasmids with different sizes. pDD-2 or pDD-neo were cotransfected with helper pAAV/Ad into Ad5 infected 293 cells. Low molecular weight DNA was extracted and digested with DpnI and analyzed on a 1% agarose gel. (A) Ethidium bromide staining. (B) Southern blot with ³²P labeled plasmid pGEM 3Z probe.

FIG. 6. Restriction analysis of rescue and replication of pDD-2. Plasmid pDD-2 was transfected into Ad5 infected or uninfected 293 cells with or without the cotransfection of helper plasmid pAAV/Ad. Low-molecular-weight DNA was digested with either SspI or ScaI and separated on a 1% agarose gel. Southern blot was done with a ³²P labeled ITR probe.

FIG. 7. Cloning of PCR-amplified and EcoRI cut dd-ITR into EcoRI site of plasmid pGEM-3'Z.

FIG. 8. *In-vitro* replication of parental plasmid containing resolvase sequences.

FIG. 9. Double-D ITR sequence (SEQ ID NO: 1).

FIG. 10. Bacterial Gamma Delta Resolvase recognition sequence (SEQ ID NO: 2).

5

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to *in vitro* construction of a novel modified AAV ITR nucleotide sequences, herein referred to as the double-D ITR sequence. The invention is based on the synthesis of a double-D ITR DNA fragment using PCR technology, and the demonstration that this fragment provides sufficient information *in cis* for replication and encapsidation of recombinant DNA fragments into mature AAV virions, or the specific integration of recombinant DNA into the host genome. The invention further relates to the use of the double-D ITR DNA sequences in eukaryotic vectors and the use of these vectors for gene replacement therapies.

20 The double-D ITR sequences may be genetically engineered into vectors designed to introduce and/or express a heterologous gene of interest. For use in gene therapy, the heterologous gene of interest may represent the normal or wild-type version of a defective or mutant gene associated with a given genetic disease. The recombinant vectors, in addition to containing the coding region for the gene of interest and the double-D ITR sequences, may contain other necessary regulatory elements such as promoter/enhancer elements, and translation and polyadenylation signals. The selection of promoter and enhancer regions will rely on the desired level and tissue specific expression of the gene of interest.

35

The transfection of recombinant vectors into a host cell line that provides helper virus function and supplies *in trans* the *REP* and *CAP* proteins allows one to obtain a recombinant virus stock (Muzyczka, N. 5 1992, Current Topics in Microbiology and Immunology 158:97-129). The resulting virus stock may then be used as a highly efficient means of delivery and transfer of new genetic information into targeted cells or tissues of choice.

10

5.1. THE AAV VIRAL SEQUENCES

The AAV genome consists of 4680 nucleotides containing two open reading frames that encode the *REP* (replication) and *CAP* (capsid) proteins. Located at 15 both ends of the genome are 145 bp inverted terminal repeats (ITRs), which are unique in that they can not only basepair with each other, but also individually fold back on themselves through the basepairing of A, A', B, B', C, C' sequences to form a T-shaped 20 structure for DNA replication when single stranded (FIG.1A).

When a plasmid containing an intact AAV genome is transfected into the adenovirus infected cells, AAV can be rescued or replicate out from the 25 plasmid vector and enter the viral lytic cycle leading to production of mature virions. In addition, if the AAV coding region is deleted and replaced by heterologous DNA sequences, the recombinant AAV can still complete the viral lytic cycle provided the ITRs 30 are intact and the *REP* and *CAP* proteins, or functional equivalents, are supplied *in trans*. However, if one of the two ITR sequences are deleted no viral DNA replication is observed indicating that both ITRs are required for AAV viability.

35

The invention is based, in part, on the discovery that the following 20 basepair D sequence (AGGAACCCCTAGTGATGGAG) (SEQ ID NO: 5) present in the ITR sequence was required for viral replication. This
5 was initially demonstrated by the inability of viral mutants with deleted D sequences to replicate their DNA. Furthermore, during the replication of a terminal resolution site mutant, natural deletions were found to occur only towards the A sequence of the
10 ITR and not towards the D end, suggesting a selection process for retention of D sequences.

In order to elucidate further the function of the D sequences, a novel modified terminal repeat structure was constructed containing a single 145 bp
15 ITR sequence with an additional 20 bp D' sequence (FIG. 9) (SEQ ID NO: 1) (See Section 6.13, *infra*). The resulting 165 bp sequence has not been identified in any naturally occurring virus. Using AAV DNA as template and a single primer derived from the D
20 sequence of the AAV ITR sequence plus 6bp of EcoRI recognition site on the 5' end, a polymerase chain reaction was performed that resulted in a DNA fragment comprised of an ITR flanked on either side by D or D' sequences as well as EcoRI sites. The PCR generated
25 DNA fragment was cleaved by EcoRI to produce sticky end, and subsequently cloned into the EcoRI site of pGEM3Z (FIG. 7). A recombinant plasmid containing the double-D ITR structure was transfected into cells to determine whether the double-D ITR was able to
30 function in replication, encapsidation, integration and rescue of recombinant DNA. Results from these experiments indicate that the novel double-D ITR sequence is sufficient to carry out the functions normally required of two wild type ITRs during a

lytic or latent AAV viral infection (See Section 6.2.3. and Section 6.2.4., infra).

5 5.2. CONSTRUCTION OF RECOMBINANT VECTORS
 COMPRISED OF AAV VIRAL SEQUENCES
 AND HETEROLOGOUS LINKED SEQUENCES

 The double-D ITR sequences (SEQ ID NO: 1) of
the invention provide the necessary information
10 required for directing the replication and
 encapsidation of recombinant DNA into mature virions.
A DNA fragment containing a double-D ITR nucleotide
sequence may be obtained by any number of methods
commonly used in the art. In a specific embodiment,
15 described herein, a polymerase chain reaction (PCR)
was used to obtain a double-D ITR DNA fragment using
AAV DNA as template and a primer derived from the D
sequence of the AAV ITR. The rationale for this
20 approach is based on the expected secondary structure
of the natural ITR sequence. In the first round of
the PCR reaction, the AAV viral IRT forms a hairpin
structure and self-primers the elongation process to
produce a long T-shaped hairpin structure containing
D and D' on the stem. Upon denaturation, this DNA
25 serves as template for a single-primed PCR reaction.
Alternative methods for isolating a double-D ITR DNA
fragment, include but are not limited to chemically
synthesizing the DNA sequence.

 Altered nucleotide sequences which may be
30 used in accordance with the invention include
derivatives and analogs of the double-D ITR sequence
that are functionally equivalent in that they retain
their ability to provide information, in *cis*, for
replication, encapsidation, integration and rescue of
35 recombinant DNA. In particular, double-D ITR
derivatives may contain additions, substitutions or

deletions of nucleotide sequences but still retain biological function.

Standard recombinant DNA methods may be used for insertion of novel double-D ITR sequences into eukaryotic expression vectors. These include *in vitro* recombinant DNA techniques, synthetic techniques and *in vivo* recombination/genetic recombination. For example, the double-D ITR DNA sequence may be amplified in a PCR reaction using oligonucleotide primers that add an appropriate restriction endonuclease recognition site onto each end of the amplified DNA fragment (See Section 6.1.3). Alternatively, any restriction site desired may be produced by ligating nucleotide sequences (linkers), comprising specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences, onto the termini of the amplified double-D fragment into an expression vector having complementary cohesive termini.

A variety of host recombinant vector systems may be utilized equally well by those skilled in the art. The recombinant vectors could contain bacterial plasmid sequences necessary for replication in *E.coli* or the *cis* acting double-D ITR sequence could be ligated directly to the gene of interest. In addition, plasmids will contain DNA sequences coding for a heterologous gene of interest, inserted between the appropriate transcriptional/translational control sequences and polyadenylation signals. A variety of promoter/enhancer elements may be used depending on the level and tissue specific expression desired. Promoters produced by recombinant DNA or synthetic techniques may be used to provide for transcription of the inserted gene of interest. Specific initiation signals are also required for efficient translation

of inserted protein coding sequences. These sequences include the ATG initiation codon and adjacent sequences. In addition, polyadenylation signals may be included to increase the stability of transcribed
5 mRNA.

One potential drawback of the AAV viral vector system is the size limitation imposed by the inability of DNA fragments larger than 5 Kb to be packaged into mature virus particles. In any given
10 expression vector, 2-3 Kb of DNA sequence derives from bacterial plasmid sequences which are required for propagation of plasmid in *E. coli*. These DNA sequences include origin of replication (*ori*) sequences and genes that confer resistance to
15 antibiotics such as ampicillin and tetracycline. In effect, this leaves only 2 Kb of space for insertion of heterologous genes of interest.

The following particular, non-limiting embodiment of the invention addresses this size
20 limitation problem. To increase the amount of space available for cloning of sequences of interest, a bacterial recombination system (γ delta) may be used to resolve plasmids in such a manner that the majority of the bacterial plasmid DNA sequences will
25 be recombined out of any given recombinant plasmid construct *in vitro*, thereby allowing for the maximum amount of space for insertion of foreign genes. The γ delta resolvase sequences may be used in a variety of viral vector systems, not limited to AAV
30 systems, as a general method for increasing the space available for insertion of foreign genes.

The parental double-D expression vector plasmid may be engineered to contain, in addition to the double-D ITR sequence, two copies of the γ delta resolution site (FIG. 10) (SEQ ID NO: 2) (120
35

basepairs) in the correct orientation so as to promote recombination when resolved *in vitro* with gamma delta resolvase enzyme. In the presence of gamma delta resolvase, the recombinant plasmid should be converted
5 into two circular DNA molecules (FIG. 8). One plasmid molecule should contain the primary bacterial plasmid sequences along with a copy of the gamma delta resolution site. The other resolved plasmid molecule would be expected to contain the double-D ITR cis
10 acting sequences, one copy of a gamma delta resolution site and the coding region for the gene of interest. It is this plasmid molecule which will be converted, in the presence of helper virus and the viral *REP* and *CAP* proteins, into a linear replicating molecule which
15 will then be encapsidated into mature viral particles.

Currently, a second plasmid is required to supply the *CAP* and *REP* proteins which are needed to convert circular plasmid molecules into replicating linear DNA fragments. In a further particular
20 embodiment of the invention, plasmids containing the gamma delta resolution sites may be engineered to also contain the coding regions for the required viral *REP* and *CAP* functions. Normally the *REP* and *CAP* coding sequences would be excluded from the expression vector
25 because they further limit the size of your insert. Using the *in vitro* recombination system, these coding regions may be included in the plasmid construct, since they will be recombined out during resolution through the two gamma delta resolution sites by the
30 resolvase enzyme (FIG. 8). The products are two concatenate DNA molecules.

Because the *in vitro* gamma delta reaction is a linear reaction, the amount of resolved molecules may be controlled in the *in vitro* resolving reaction
35 to generate desired ratios of parental plasmid to

resolved circles. The mixture of plasmids can then be transfected into the host cell. This introduces one circular molecule containing the AAV *REP* and *CAP* genes required *in trans* for a productive replication, and
5 the other circular molecule contains the double-D ITR sequences and the gene of interest. The double-D circular molecule may be replicated into a linear DNA molecule which may subsequently be encapsidated into viral particles by the *trans* factors introduced on the
10 *REP/CAP* circular plasmid.

The present invention further provides for the analogous use of the above-described gamma delta resolvase system to first propagate plasmids that comprise (i) a recombinant viral vector sequence
15 comprising a gene of interest, (ii) viral genes providing helper functions, and (iii) two gamma delta resolvase recognition sequences flanking the viral vector sequence (SEQ ID NO: 2) and, second, to separate recombinant viral vector sequences comprising
20 the gene of interest from the remaining plasmid sequence using resolvase enzyme. According to these methods, the virus from which the vector and helper functions are derived may be any suitable virus including but not limited to AAV, a retrovirus,
25 adenovirus, or herpes virus. In preferred embodiments the viral vector portion of the plasmid comprises the double-D ITR sequence or, alternatively, both AAV ITR's. In general, the viral vector protein comprises sequences necessary for encapsidation and
30 transcription of the gene of interest.

5.3. PRODUCTION OF RECOMBINANT VIRUS STOCKS

The invention relates to a method for replicating and encapsidating a recombinant DNA
35 molecule into an AAV particle which comprises

culturing a eukaryotic cell containing helper virus, recombinant DNA encoding AAV *REP* and *CAP* proteins, and a recombinant nucleic acid containing a DNA sequence of interest and the 165 base pair double-D ITR
5 sequence.

To generate recombinant viral stocks, the double-D ITR recombinant expression vector plasmid may be transfected into a host cell line that is able to provide helper virus function, and supply *in trans* AAV
10 *REP* and *CAP* proteins. The *REP* and *CAP* proteins are required for replication and encapsidation of the linear recombinant DNA into mature viral particles.

The *REP* and *CAP* proteins may be supplied *in trans* by transfection of the host cell line with a
15 recombinant plasmid that is capable of coding for each of the proteins. DNA transfections may be carried out using methods well known to those skilled in the art. These may include DNA transfection by lipofection, electroporation or calcium phosphate precipitation
20 [Ausubel, et al., 1989, in Current Protocols for Molecular Biology,]. The plasmid is transfected into the host cell line with the intention of either transiently or stably expressing the *REP* and *CAP* proteins. In a specific embodiment, described in
25 Section 6.1., the plasmid pAAV/AD containing the AAV coding regions, was transfected into a host cell for the purpose of expressing the *REP* and *CAP* proteins.

In another embodiment, the double-D ITR expression vector may be engineered to directly
30 express the *REP* and *CAP* proteins. In this case, it is also important to include the gamma delta resolvase sequences in the plasmid vector, so that the *REP* and *CAP* coding regions may be recombined out during an *in vitro* resolvase reaction so as not to impose a size
35 limitation on the insert of foreign DNA.

In addition to expressing the viral *REP* and *CAP* proteins, the host cell lines must be able to provide helper virus function. Both adenovirus and herpes simplex virus may serve as helper viruses for replication of DNA fragments containing the double-D ITR sequences. Any host cell permissive for infection by either of these two viruses or any virus that acts as a helper virus for AAV, may be used in the practice of the invention. The multiplicity of infection (MOI) and the duration of the infection time will depend on the type of virus used and the cell line employed.

In a specific embodiment, described herein, 293 cells which had previously been transfected with a recombinant double-D ITR expression vector, were infected with Ad5 at a MOI of 10. Forty-eight hours later the cells were frozen and thawed three times, and incubated for one hour at 56°C to inactivate the adenovirus. The resulting cell lysate contains recombinant viral particles that may be used to infect cells or tissue of choice.

5.4. USES OF RECOMBINANT VECTORS

There are numerous human genetic disorders from which patients suffer, which include diseases such as sickle cell anemia, thalassemias, Lesch-Nyhan disease and cystic fibrosis. Current therapies do little to alleviate the symptoms associated with these diseases and efforts are currently underway to develop new methods for the treatment of genetic diseases.

Recent advances in molecular techniques have made it possible to isolate the normal complement of a given defective gene and this has led to the concept of "gene therapy", and the acceptance of gene therapy as a feasible means of treatment for those suffering from genetic disorders. Until recently, retroviruses

were the most widely researched viral vectors for use in gene therapy. Unfortunately, a number of difficulties are associated with retroviral use which include the random integration of retroviral DNA into the host chromosome leading to insertional mutagenesis or activation of protooncogene expression.

AAV vectors provide a viable alternative to the retroviral systems for use in gene therapy. The nonrandom integration of AAV into the host chromosome and the lack of transcriptional activity associated with the ITR structures indicate that AAV may be particularly beneficial for treatment of genetic disorders.

The double-D ITR expression vectors, containing a gene of interest and described herein, may be useful for therapeutic treatment of genetic disorders. The gene of interest may be the wild type complement of any mutated or defective gene and may be inserted into the double-D ITR recombinant vectors so that its expression is controlled by its natural promoter (e.g., so that expression is regulated normally) or by a heterologous promoter. A recombinant viral stock may be generated by transfection of the double-D ITR plasmid into a suitable host cell line that first allows for conversion of a circular duplex molecule into a linear DNA molecule covalently closed at both ends. This then permits replication and encapsidation of recombinant DNA into mature viral particles. The resulting viral stocks may then be used to infect tissue or cells affected by the genetic defect.

6. EXAMPLE: A NOVEL 165 BASE PAIR TERMINAL REPEAT IS THE ONLY *cis*-ELEMENT REQUIRED FOR ADENO-ASSOCIATED VIRUS LIFE CYCLE

5 The subsection below describes the synthesis and functional characterization of the double-D ITR sequence.

6.1. MATERIALS AND METHODS

6.1.1. DNA TRANSFECTION

10 Human cell line 293 was maintained in DMEM (Dulbecco modified Eagle medium, GIBCO) WITH 10% FCS (fetal calf serum, HyClone). Transfection of plasmid DNA was done by lipofectin (BRL) method as described by the manufacturer. Briefly, cells in a 6-cm dish were washed twice with DMEM and infected with
15 Adenovirus 5 at 10 moi (multiplicity of infection) in 1ml Opti-MEM (GIBCO) for 1 hr. Then 5 ug plasmid DNA was incubated with 50 ul of lipofectin (BRL) at room temperature for 10 min, mixed with 2 ml of Opti-MEM and added to the Adenovirus infected cells. After
20 incubation for 12 hrs., the cells were fed with 3 ml of DMEM containing 4% FCS and incubated for an additional 36 hours.

25

6.1.2. SOUTHERN HYBRIDIZATION

Low molecular weight DNA from transfected cells was extracted as described by Hirt (Hirt, B.1967, J. Mol. Biol. 26:365-369). The DNA was digested by restriction enzymes (New England BioLab),
30 separated on an agarose gel, then transferred onto the Genescreen plus Nylon membrane (DuPont). Hybridization with ³²P labeled plasmid DNA was carried out as recommended by the manufacturer. Hybridization with r- ³²P-ATP end-labeled ITR oligonucleotide probe
35 A-1 (5'TTGCCACTCCCTCTCTGCG3') (SEQ ID NO: 4), derived

from A region of ITR, kindly provided by N. Muzyczka) was performed as follows: the membrane was prehybridized in 10 ml solution containing 5X SSC, 10X Denhardt's solution, 10% dextran sulfate and 5% SDS at 60°C for at least 1 hr. 25 ng of ³²P end labeled oligo-probe and 200 ug heat-denatured salmon sperm DNA in 0.5 ml H₂O were added. Hybridization was continued at 60°C overnight. The membrane was washed twice in 3X SSC and 5% SDS at 60°C for 30 minutes and once in 0.2X SSC at room temperature for 10 minutes.

6.1.3. PCR AND CONSTRUCTION OF ITR PLASMID

Low molecular weight DNA from AAV and Ad5 infected cells was used as template for the PCR reaction with a single primer derived from D-sequence of AAV. The PCR was performed at 94°C 1 min., 45°C 30 seconds and 72°C 1 min. for 35 cycles in a 50 ul reaction solution containing 20 mM Tris-HCl (pH8.8), 1.5 mM MgCl₂, 50 mM KCl, 2.5% formamide, 100 uM dATP, dCTP and dTTP, 75 uM 7-deazo-dGTP, 25 uM dGTP, 1.5U AmpliTaq (Perkin Elmer Cetus), 1 ng AAV DNA and 100 pmole primer TR-1 (5'-GGAATTCAGGAACCCCTAGTGATGG3-3') (SEQ ID NO: 3). The PCR product was purified by agarose gel electrophoresis, cut with EcoRI and ligated with an EcoRI cut and dephosphorylated pGEM 3Z plasmid (Promega). The ligated plasmid was transformed into *E.coli* Sure strain (Stratagene). Positive clones named pDD's were screened for the presence of double-D terminal repeat and confirmed by dideoxy-sequencing with 7-deazo-dGTP substituted for dGTP (Sanger, F. et al., 1977, Proc. Natl. Acad. Sci. USA 74:5463-5467). Subsequently, a neo gene was cloned into the SalI site of pDD-2 resulting in the plasmid pDD-neo.

35

6.1.4. CLONING OF NEO-RESISTANT CELL LINES

Ad5 infected 293 cells were cotransfected with pDD-neo and pAAV/Ad [Samulski, et.al., 1989. J. Virol. 63:3822-3828] for 48 hrs. The cells were
5 frozen and thawed three times and then incubated at 56_C for 1 hour to inactivate the Ad5 virus. The cell lysate containing the DD-neo recombinant AAV virus was used to infect the human cell line Detroit 6. The cells were inoculated for 24 hours, then selected with
10 G418 at 400ug/ml to obtain neo-resistant clones. Various clones were superinfected with wild-type AAV and Ad5 at a MOI of 10 to rescue the latent neo-AAV.

6.2. RESULTS

15 6.2.1. CONSTRUCTION OF ITR WITH DOUBLE D SEQUENCE

The Polymerase Chain Reaction (PCR) was used to construct the inverted terminal repeat with a D' sequence added to the other end. The rationale is based on the T-shape structure of the ITR. In the
20 first round of PCR reaction, the AAV viral IRT will self-prime the elongation to produce a long T-shaped hairpin structure containing D and D' on the stem. Upon denaturation, this DNA can serve as template for single-primed PCR.

25 Owing to the high GC content and the strong palindromic structure in the ITR region, several strategies such as 7-deazo-dGTP, 2.5% formamide, and high concentration of primer were utilized to tackle the PCR problems and yield sufficient desired PCR
30 product. For the convenience of cloning, an EcoRI recognition sequence was attached to the 5' of the primer so that the PCR product can be cut by EcoRI and easily cloned into the polylinker of pGEM 3Z. Due to the instability of the ITR in bacteria host, the
35 recombinant plasmid was transformed into an *E.coli*

SURE strain (Stratagene) in which the ITR was rather stable. By using the above strategy, we obtained numerous positive clones. Some clones were characterized by restriction digestion and sequencing.

- 5 One of the clones is shown in Figure 2 bearing an insert of D'ABB'CC'A'D in the EcoRI site of the pGEM-3Z. This plasmid was named pDD-2 and was used in the following transfection experiments.

10 6.2.2. pDD-2 REPLICATION IS DEPENDENT ON REP

In order to assay the capability for replication, Plasmid pDD-2 was transfected into Ad5 infected 293 cells with or without cotransfection of a helper plasmid pAAV/Ad, which contains functional *REP* and *CAP* genes but without the ITR, so that it can not replicate. Due to the lack of functional origins this molecule can only supply *REP* and *CAP* proteins in trans. Post transfection for 48 hours, the plasmid DNA was extracted and separated on 1% agarose gel with or without DpnI digestion. DpnI only digests the input methylated plasmid DNA while leaving the replicated (demethylated) DNA intact. The results demonstrated that in the absence of the helper plasmid, pDD-2 plasmid did not replicate therefore the DNA is completely DpnI sensitive (FIG. 3, lane 1 and 2). However, in the presence of the helper plasmid, pDD-2 replicated very efficiently as evidenced by the resistance to DpnI digestion and the existence of monomer and dimer molecules: the typical AAV replication pattern (FIG. 3, lane 3 and 4). The pDD-2 replication is dependent on two factors: the DD-ITR in-cis and *REP* gene products in-trans, because the cloning vector pGEM-3Z did not replicate under the same conditions and a plasmid containing only *REP* gene

without *CAP* gene can also supply the helper function in trans for pDD-2 (data not shown).

Since the replication of pDD-2 with one modified ITR was very efficient, a comparison was made
5 between pDD-2 and two other infectious AAV plasmids, psub201 [Samulski, et.al., 1987. *J. Virol*, 61:3096-3101.] and pSM620 [Samulski, et.al., 1982, *Proc. Natl. Acad. Sci. U.S.A.* 79:2077-2081.], which possesses two ITRs as well as wild type *REP* and *CAP* genes. The pDD-
10 2 was cotransfected into Ad5 infected cells with equal amounts of either pAAV/Ad helper (without ITR), psub201 or pSM620. The plasmid DNA was extracted 2 days post transfection, digested with DpnI, separated on 1% agarose gel. Southern blot was performed with
15 an oligonucleotide probe from the A sequence of the ITR so that it can detect all the replicated DNA containing ITRs. As shown in Figure 4, all three plasmids containing AAV coding genes can complement the pDD-2 replication equally well. However, psub201
20 itself replicated at a much lower level although it can complement pDD-2 replication effectively. pSM201 replicated at a similar level as pDD-2.

In order to determine whether the effectiveness of pDD-2 replication was due to the
25 special DD-ITR or due to the smaller size of the plasmid (2.9 kb), a neo gene fragment of 1.2 kb was inserted into the *Sal*I site at the polylinker of pDD-2. The new plasmid pDD-neo is 4.1 kb in size, close to the size of wild type AAV (4.68 kb). This plasmid
30 converted from a duplex circular to a linear molecule and replicated as efficiently as the parental pDD-2 (FIG. 5). DD-ITR plasmids were constructed with sizes up to 7.5 kb. These molecules also efficiently replicate (data not shown). The above results suggest

that the DD-ITR is an excellent substrate for Rep-dependent replication.

6.2.3. REPLICATION AND RESCUE IS VIA AAV MECHANISM

5 AAV inverted terminal repeats have been proven to be the viral replication origins. *In vitro*, these sequences are recognized as a substrate by *REP* protein, a site-and-strand-specific nickase and helicase. ITRs have also been considered as the
10 substrate for AAV rescue [Muzyczka, N. 1992, Current Topics in Microbiology & Immunology. 158, 97-129]. Since the double-D plasmids contain one unique ITR and we have demonstrated that this sequence replicates only in the presence of *REP* proteins, it is attractive
15 to predict that the rescue and replication are through similar AAV rescue and replication mechanisms (FIG. 1, A and B).

In order to test the above assumption, pDD-2 DNA was transfected into Ad5 infected 293 cells with
20 or without helper plasmid, or transfected into uninfected 293 cells. Subsequently, the plasmid DNA was subjected to restriction analysis by two single cutter enzymes *ScpI* and *ScaI* respectively (for map, see FIG. 2). The DNA was probed with ITR
25 oligonucleotide so that only the ITR-containing fragments would be detected. The results are shown in Figure 6. After *SspI* or *ScaI* digestion, a linear full length plasmid band could be observed throughout all the lanes (P to 6). This band was derived from the
30 unresolved input circular plasmid. While in lane 1 and 4 (Ad5 plus helper plasmid), four additional bands with expected molecular weight could also be seen. Two of them arose from internal head-to-head and tail-to-tail fragments of the digested dimer molecules..
35 The other two bands are derived by digested monomer

and dimer external fragments, most likely suggesting that pDD-2 is resolved at the unique double D ITR site and replicated via AAV replication scheme. It is noteworthy that in Ad5 infected cells (lane 2 and 5) and uninfected cells (lane 3 and 6), two fainter bands from the resolved monomer were also visible, suggesting that some cellular mechanism can initiate the rescue process at the double D ITR site in the absence of any other AAV sequence or AAV gene product. Although, such rescued DNA could not replicate in the absence of Rep proteins (see FIG. 3, lane 2) this suggests that the double D substrate may confer special features involved in the first step of AAV recognition not seen with the conventional AAV plasmids containing two wild type ITR's.

6.2.4. ONE DD-ITR IN-CIS IS SUFFICIENT FOR AAV VIABILITY

Since plasmids with a single modified DD-ITR could efficiently replicate like wild type AAV, the following questions were consequently asked: can this replicated DNA be encapsidated into virions. If so, can these virions infect cells and establish a latent infection by integration into cellular DNA. Finally, can these latent sequences be subsequently rescued out away from the chromosomes and re-enter the productive pathway upon superinfection with the wild type AAV and adenovirus.

In an effort to address the above questions, plasmid pDD-neo was used to generate the DD-neo virus preparation as described in Section 6.1.4. The cell lysates containing the recombinant virus particles were then used to infect human Detroit 6 cells. Two weeks post infection cells were selected against G418. A number of neo-resistant clones were isolated, indicating that the recombinant viruses were made and

transduction was accomplished. DD-neo cell lines were superinfected with wild type AAV-2 and Ad5 and assayed for transduced DNA rescue and replication. Then the viral DNA was extracted and probed with a neo gene
5 fragment. Examples of DD-neo cell lines that rescued DD-neo viral DNA replicated as monomer and dimer (data not shown). These results demonstrated that the 165 bp single DD-ITR is the only cis-sequence required to fulfill all the steps in AAV life cycle. Thus, the
10 processes such as rescue from the plasmid, replication of the DNA, encapsidation of the virus, infection into the cells, integration into the chromosome and rescue back again were all mediated by this unique double D inverted terminal repeat sequence.

15 The present invention is not to be limited in scope by the exemplified embodiments disclosed herein which are intended as illustrations of single aspects of the invention, and any clones, DNA or amino acid sequences which are functionally equivalent are
20 within the scope of the invention. Indeed, various modifications of the invention, in addition to those shown and described herein, will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such
25 modifications are intended to fall within the scope of the appended claims.

It is also to be understood that all base pair and amino acid residue numbers and sizes given for nucleotides and peptides are approximate and used
30 for the purposes of description.

Various publications are cited herein that are hereby incorporated by reference in their entireties.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Samulski, R. J.
Xiao, X.
- (ii) TITLE OF INVENTION: Recombinant Viral Vector System
- (iii) NUMBER OF SEQUENCES: 5
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Pennie & Edmonds
 - (B) STREET: 1155 Avenue of the Americas
 - (C) CITY: New York
 - (D) STATE: New York
 - (E) COUNTRY: U.S.A.
 - (F) ZIP: 10036-2711
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: To be assigned
 - (B) FILING DATE: On even date herewith
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Coruzzi, Laura A
 - (B) REGISTRATION NUMBER: 30,742
 - (C) REFERENCE/DOCKET NUMBER: 6636-013
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (212) 790-9090
 - (B) TELEFAX: (212) 869-8864/9741
 - (C) TELEX: 66141 PENNIE

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 165 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: unknown

- (ii) MOLECULE TYPE: DNA (genomic)

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```

AGGAACCCCT AGTGATGGAG TTGCCACTC CCTCTCTGCG CGCTCGCTCG CTCACTGAGG      60
CCGGGCGACC AAAGGTCGCC CGACGCCCGG GCTTTGCCCG GCGGCCTCA GTGAGCGAGC      120
GAGCGCGCAG AGAGGGAGTG GCCAACTCCA TCACTAGGGG TTCCT                      165

```

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 120 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: unknown
- (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CCCTGTATCC TAAATCAAAT ATCGGACAAG CAGTGTCTGT TATAACAAA AATCGATTTA 60
ATAGACACAC CAACAGCATG GTTTTTATGT GTGCGATAAT TTATAATATT TCGGACAGGG 120

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GGAATTCAGG AACCCCTAGT GATGG 25

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

TTGGCCACTC CCTCTCTGCG 20

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

AGGAACCCCT AGTGATGGAG 20

WHAT IS CLAIMED IS:

1. A purified and isolated nucleic acid molecule comprising a 165 base pair inverted terminal repeat sequence as depicted in Figure 9 (SEQ ID NO: 1).

5

2. A recombinant DNA vector comprising a DNA nucleotide sequence encoding a protein of interest and a 165 base pair inverted terminal repeat sequence as depicted in Figure 9 (SEQ ID NO: 1).

10

3. The recombinant DNA vector according to claim 2 further comprising a DNA nucleotide sequence that encodes the AAV REP and CAP proteins.

15

4. The recombinant DNA vector according to claim 2 further comprising a DNA nucleotide sequence recognized by bacterial gamma delta resolvase as depicted in Figure 10 (SEQ ID NO: 2).

20

5. The recombinant DNA vector according to claim 3 further comprising a DNA nucleotide sequence recognized by bacterial gamma delta resolvase as depicted in Figure 10 (SEQ ID NO: 2).

25

6. A method of replicating and encapsidating a recombinant DNA molecule into an AAV particle, comprising: culturing a eukaryotic cell containing a helper virus, a recombinant nucleic acid encoding AAV REP and CAP proteins, and a recombinant nucleic acid that contains a DNA sequence of interest and a 165 base pair inverted terminal repeat sequence as depicted in Figure 9 (SEQ ID NO: 1); whereby the nucleic acid containing the 165 base pair inverted terminal repeat sequence and the DNA sequence of

35

interest is replicated and assembled into an AAV particle.

7. The method according to claim 6 in which the
5 helper virus is an adenovirus.

8. The method according to claim 6 in which the
helper virus is a herpes simplex virus.

10 9. The method according to claim 6 in which the
recombinant nucleic acid encoding the AAV REP and CAP
proteins is a plasmid vector comprising:

(a) promoters which control the expression of
the AAV REP and CAP RNA;

15 (b) translation initiation signals for the REP
and CAP mRNA;

(c) DNA sequences encoding the REP and CAP
proteins; and

(d) transcriptional termination signals.

20

10. The method according to claim 6 in which the
recombinant nucleic acid containing the DNA sequence
of interest and the 165 base pair terminal repeat
sequence is a plasmid vector comprising:

25 (a) a promoter;

(b) a DNA sequence of interest transcribed under
the control of the promoter; and

(c) a 165 base pair inverted terminal repeat
sequence as depicted in Figure 9 (SEQ ID NO: 1).

30

11. A method of replicating and encapsidating a
recombinant DNA molecule into a viral particle
comprising:

(a) propagating a recombinant nucleic acid
35 comprising (i) a recombinant viral vector sequence

comprising a gene of interest; (ii) viral genes providing helper functions; and (iii) two bacterial gamma delta resolvase recognition sequences as depicted in Figure 10 (SEQ ID NO: 2) flanking the
5 viral vector sequence;

(b) treating the propagated nucleic acid with bacterial gamma delta resolvase; and

(c) culturing a eukaryotic cell containing a helper virus and said resolvase treated recombinant
10 nucleic acid; whereby the resolved recombinant DNA is replicated and encapsidated into a viral particle.

12. A method of replicating and encapsidating a recombinant DNA molecule into an AAV particle
15 comprising:

(a) treating a recombinant nucleic acid comprising a 165 base pair terminal repeat sequence as depicted in Figure 9 (SEQ ID NO: 1) and a bacterial gamma delta resolvase recognition sequence as depicted
20 in Figure 10 (SEQ ID NO: 2), with bacterial gamma resolvase enzyme; and

(b) culturing a eukaryotic cell containing a helper virus and said resolvase treated recombinant nucleic acid; whereby the resolved recombinant nucleic
25 acid is replicated and encapsidated into an AAV particle.

13. The method according to claim 12 in which the helper virus is an adenovirus.
30

14. The method according to claim 12 in which the helper virus is a herpes simplex virus.

15. The method according to claim 12 in which
35 the recombinant nucleic acid containing the bacterial

gamma delta resolvase recognition sequence is a plasmid vector comprising:

(a) a bacterial gamma delta resolvase recognition sequence;

5 (b) a promoter;

(c) a DNA sequence of interest transcribed under the control of a promoter; and

(d) a 165 base pair inverted terminal repeat sequence as depicted in Figure 9 (SEQ ID NO: 1).

10

16. The method according to claim 12 in which the recombinant nucleic acid containing the bacterial gamma delta resolvase recognition sequence is a plasmid vector comprising:

15 (a) a bacterial gamma delta resolvase recognition sequence;

(b) a promoter;

(c) a DNA sequence of interest transcribed under the control of a promoter;

20 (d) a 165 base pair inverted terminal repeat sequence as depicted in Figure 9 (SEQ ID NO: 1); and

(e) a DNA nucleotide sequence that encodes the AAV REP and CAP proteins.

25

30

35

- 1/12 -








Figure 1A

- 2/12 -



No D sequence

Figure 1B

- 3/12 -




Figure 1.C.

- 4/12 -




Figure 2. Rescue intermediate from circular DD-ITR plasmid.

- 5/12 -





FIG 3

-6/12-

FIG 4



-7/12-




FIG. 5

- 8/12 -




FIG. 6

-9/12-




FIG. 7

-10/12-




FIG. 8

- 11/12 -

5'-AGGAACCCCT AGTGATGGAG TTGGCCACTC CCTCTCTGCG CGCTCGCTCG CTCACTGAGG 60
CCGGGCGACC AAAGGTCGCC CGACGCCCGG GCTTTGCCCG GCGGGCCTCA GTGAGCGGAGC 120
GAGCGGCGAG AGAGGGAGTG GCCAACTCCA TCACTAGGGG TTCCT -3' 165

DOUBLE-D ITR SEQUENCE

FIG. 9

-12/12-

5'-CCCCGTATCC TAAATCAANT ATCGGACAG CAGTGTCTGT TATAACANNA AATCGATTTA 60
ATAGACACAC CAACAGCATG GTTTTATGT GTCCGATANT TATATATATT TCGGACAGGG -3' 120

GAMMA DELTA RESOLVASE SEQUENCE

FIG. 10

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/11728

<p>A. CLASSIFICATION OF SUBJECT MATTER IPC(5) : C12N 7/01, 15/85, 15/86, 15/79 US CL : 435/69.1, 320.1, 172.3, 235.1; 536/23.1, 24.1 According to International Patent Classification (IPC) or to both national classification and IPC</p>														
<p>B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/69.1, 320.1, 172.3, 235.1; 536/23.1, 24.1 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) APS, MEDLINE, Dialog, Biosis Search terms: adenovirus, expresion vector, terminal repeat</p>														
<p>C. DOCUMENTS CONSIDERED TO BE RELEVANT</p> <table border="1"> <thead> <tr> <th>Category*</th> <th>Citation of document, with indication, where appropriate, of the relevant passages</th> <th>Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td>A</td> <td>US, A, 4,797,368 (CARTER et al.) 10 January 1989, See whole document, particularly Figure 1.</td> <td>1-16</td> </tr> <tr> <td>A</td> <td>US, A, 5,139,941 (MUZYCZKA et al.) 18 August 1992, See whole document, particularly Columns 9 and 10.</td> <td>1-16</td> </tr> </tbody> </table>			Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	A	US, A, 4,797,368 (CARTER et al.) 10 January 1989, See whole document, particularly Figure 1.	1-16	A	US, A, 5,139,941 (MUZYCZKA et al.) 18 August 1992, See whole document, particularly Columns 9 and 10.	1-16			
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
A	US, A, 4,797,368 (CARTER et al.) 10 January 1989, See whole document, particularly Figure 1.	1-16												
A	US, A, 5,139,941 (MUZYCZKA et al.) 18 August 1992, See whole document, particularly Columns 9 and 10.	1-16												
<p><input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.</p>														
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"A" document defining the general state of the art which is not considered to be part of particular relevance</td> <td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"E" earlier document published on or after the international filing date</td> <td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"&" document member of the same patent family</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td></td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"A" document defining the general state of the art which is not considered to be part of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family	"O" document referring to an oral disclosure, use, exhibition or other means		"P" document published prior to the international filing date but later than the priority date claimed	
* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention													
"A" document defining the general state of the art which is not considered to be part of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone													
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art													
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family													
"O" document referring to an oral disclosure, use, exhibition or other means														
"P" document published prior to the international filing date but later than the priority date claimed														
Date of the actual completion of the international search 17 February 1994		Date of mailing of the international search report 10 MAR 1994												
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. NOT APPLICABLE		Authorized officer DAVID GUZO <i>Jill Warden for</i> Telephone No. (703) 308-0196												